



## Oliver Dorigo, M.D., Ph.D.

Mary Lake Polan Professor

Obstetrics & Gynecology - Gynecologic Oncology

### CLINICAL OFFICE (PRIMARY)

- **Stanford Women's Cancer Center**

900 Blake Wilbur Dr

1st Fl MC 5854

Palo Alto, CA 94304

**Tel** (650) 498-6004

**Fax** (650) 498-7237

### ACADEMIC CONTACT INFORMATION

- **Alternate Contact**

Helen Wong - Administrative Assistant

**Email** [hswong@stanford.edu](mailto:hswong@stanford.edu)

**Tel** (650) 724-0456

## Bio

---

### CLINICAL FOCUS

- Cancer > Gynecologic Cancer
- Gynecologic Oncology

### ACADEMIC APPOINTMENTS

- Professor - University Medical Line, Obstetrics & Gynecology - Gynecologic Oncology
- Member, Bio-X
- Member, Stanford Cancer Institute

### ADMINISTRATIVE APPOINTMENTS

- Director, Stanford Gynecologic Oncology Fellowship, (2016- present)
- Director, Stanford Clinical Research Group for Gynecologic Cancer Trials, (2014- present)
- Director, Stanford Gynecologic Oncology Clinical Care Program, (2013- present)
- Director, Mary Lake Polan Gynecologic Oncology Research Laboratory, (2013- present)
- Director, Stanford Obstetrics and Gynecology, Division of Gynecologic Oncology, (2013- present)

### HONORS AND AWARDS

- American Association of Cancer Research Outstanding Poster Award, Toronto, Canada, American Association of Cancer Research, Toronto, Canada (1995)
- Outstanding Podium Presentation Award, National Gynecologic Oncology Fellow's Forum (2004)
- Teaching Award, National Council on Resident Education in Obstetrics and Gynecology (2007)
- STOP Cancer Career Development Award, STOP Cancer (2008)
- OB/GYN Resident Teaching Award, University of California, Los Angeles (2008)

## **BOARDS, ADVISORY COMMITTEES, PROFESSIONAL ORGANIZATIONS**

- Member, Society of Pelvic Surgeons (2016 - present)
- Member, American Association of Cancer Research (1996 - present)
- Member, American Gynecological and Obstetrical Society (2016 - present)
- Member, Society of Gynecologic Investigations (2000 - present)
- Member, American Society of Gene Therapy (2000 - present)
- Member, Society of Gynecologic Oncology (2005 - present)
- Member, Gynecologic Oncology Group (2005 - present)

## **PROFESSIONAL EDUCATION**

- Fellowship: UCLA Medical Center Obstetrics and Gynecology Fellowships (2005) CA
- Residency: UCLA Medical Center Obstetrics and Gynecology Residency (1999) CA
- Medical Education: University of Heidelberg (1989) Germany
- Board Certification: Gynecologic Oncology, American Board of Obstetrics and Gynecology (2008)
- Board Certification: Obstetrics and Gynecology, American Board of Obstetrics and Gynecology (2006)
- PhD, University of California, Los Angeles , Molecular Biology (2003)
- Residency: Ludwig Maximillians University (1992) Germany

## **Research & Scholarship**

---

### **CLINICAL TRIALS**

- A Study of PHST001 in Advanced Solid Tumors, Recruiting
- Clinical Trial of Autologous B7-H3 CAR T Cells in Reoccurent Platinum-resistant Ovarian Tumors, Recruiting
- A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer, Not Recruiting
- A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, Not Recruiting
- A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens, Not Recruiting
- A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2), Not Recruiting
- A Study of Sapanisertib, Combination of Sapanisertib With MLN1117, Paclitaxel and Combination of Sapanisertib With Paclitaxel in Women With Endometrial Cancer, Not Recruiting
- Acalabrutinib (ACP-196) Alone and in Combination With Pembrolizumab in Ovarian Cancer (KEYNOTE191), Not Recruiting
- Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected, Not Recruiting
- Bintrafusp Alfa Combination Therapy in Participants With Cervical Cancer (INTR@PID 046), Not Recruiting
- Bintrafusp Alfa Monotherapy in Platinum-Experienced Cervical Cancer, Not Recruiting
- Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer, Not Recruiting
- Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer, Not Recruiting
- Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer, Not Recruiting
- Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients, Not Recruiting
- CT Antigen TCR-redirected T Cells for Ovarian Cancer., Not Recruiting

- Cvac as Maintenance Treatment in Patients With Epithelial Ovarian Cancer in Complete Remission Following First-line Chemotherapy or Second-line Treatment, Not Recruiting
- Feasibility Study of New Method of Diagnostic and Prediction of Painful CIPN, Not Recruiting
- Health and Recovery Program in Increasing Physical Activity Level in Stage IA-IIIa Endometrial Cancer Survivors, Not Recruiting
- Maveuropepimut-S (MVP-S) and Low-Dose CPA in Patients With Platinum-Resistant Ovarian Cancer, Not Recruiting
- Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy., Not Recruiting
- OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission, Not Recruiting
- Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer, Not Recruiting
- Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer, Not Recruiting
- Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer, Not Recruiting
- Safety and Efficacy of CRS-207 With Epcadostat in Platinum Resistant Ovarian, Fallopian or Peritoneal Cancer, Not Recruiting
- Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules, Not Recruiting
- Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer, Not Recruiting
- Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies, Not Recruiting
- Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer, Not Recruiting
- Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer, Not Recruiting
- TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer, Not Recruiting
- Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, Not Recruiting
- Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, Not Recruiting
- VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer, Not Recruiting

## Teaching

---

### STANFORD ADVISEES

#### Postdoctoral Faculty Sponsor

Huyen Pham

#### Doctoral Dissertation Reader (NonAC)

Natalie Pilla

## Publications

---

### PUBLICATIONS

- **Macrophage-derived CCL23 upregulates expression of T-cell exhaustion markers in ovarian cancer.** *British journal of cancer*  
Kamat, K., Krishnan, V., Dorigo, O.  
2022
- **Omental macrophages secrete chemokine ligands that promote ovarian cancer colonization of the omentum via CCR1.** *Communications biology*  
Krishnan, V., Tallapragada, S., Schaar, B., Kamat, K., Chanana, A. M., Zhang, Y., Patel, S., Parkash, V., Rinker-Schaeffer, C., Folkins, A. K., Rankin, E. B., Dorigo, O.  
2020; 3 (1): 524

- **Molecular profiling and tumour biomarker analysis of GOG281/LOGS: a positive late-phase trial of trametinib for recurrent/persistent low grade-serous ovarian cancer.** *Clinical cancer research : an official journal of the American Association for Cancer Research*  
Hollis, R. L., Miller, A., Lankes, H. A., Wong, K. K., Rodgers, W., Millan, D., Carty, K., Coleman, R. L., Moore, K. N., Alvarez Secord, A., O'Malley, D. M., Chan, J. K., Hagemann, et al  
2025
- **Durable response to an anti-CD25 antibody-drug conjugate and anti-PD-1 antibody in ovarian carcinoma: a case report.** *Immunotherapy*  
Bekheet, F., Ashland, M., Reyes, R., Dorigo, O., Karam, A., Chen, C. T.  
2025: 1-5
- **Obesity, demographic, and lifestyle risk factor patterns associated with endometrial cancer diagnosis and survival: insights from the Women's Health Initiative** *EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY*  
Somasegar, S., Hedlin, H., Kurian, A. W., Kroenke, C., Dorigo, O., Stefanick, M. L.  
2025; 46 (8): 11-25
- **Early experience and assessment of real-world toxicities with mirvetuximab soravtansine in a heavily pretreated patient cohort with ovarian cancer.** *Gynecologic oncology reports*  
Lang, S. M., Vingopoulos, F., Beshar, I., Somasegar, S., Adams, E. V., Sasse, S. A., Ghezelayagh, T., McClung, E. C., Karam, A., Dorigo, O., Mruthunjaya, P., Litkouhi, B.  
2025; 59: 101738
- **Active Forms of Chemerin Are Elevated in Human and Mouse Ovarian Carcinoma.** *Biomedicines*  
Zhao, L., Zhou, Q., Krishnan, V., Chan, J., Sasse, S., Tallapragada, S., Eisenberg, D., Leung, L., Dorigo, O., Morser, J.  
2025; 13 (4)
- **Fertility-sparing treatment for atypical polypoid adenomyoma** *GYNECOLOGIC ONCOLOGY REPORTS*  
Beshar, I., Lang, S., Dorigo, O., Howitt, B. E., Liu, C., Karam, A.  
2025; 58
- **Long term treatment of advanced endometrial cancer with lenvatinib and pembrolizumab** *GYNECOLOGIC ONCOLOGY REPORTS*  
Somasegar, S., Sousa, B., Jairam-Thodla, A., Dorigo, O.  
2025; 58
- **Fertility-sparing treatment for atypical polypoid adenomyoma.** *Gynecologic oncology reports*  
Beshar, I., Lang, S., Dorigo, O., Howitt, B. E., Liu, C., Karam, A.  
2025; 58: 101714
- **Long term treatment of advanced endometrial cancer with lenvatinib and pembrolizumab.** *Gynecologic oncology reports*  
Somasegar, S., Msn, B. S., Jairam-Thodla, A., Dorigo, O.  
2025; 58: 101717
- **Clinical Response to Enfortumab Vedotin and Pembrolizumab in a Patient with Vaginal Squamous Cell Carcinoma: A Case Report.** *Case reports in oncology*  
Glover, M., Beshar, I., McHenry, A., Ding, C., Dorigo, O., Chan, E., Shah, S. A.  
2025; 18 (1): 473-479
- **EVEREST-2: A seamless phase 1/2 study of A2B694, a logic-gated Tmod chimeric antigen receptor T-cell (CAR T) therapy, in patients with pancreatic cancer (PANC) or other mesothelin (MSLN)-expressing solid tumors and human leukocyte antigen (HLA)-A\*02 loss of heterozygosity (LOH).**  
Spencer, K., Punekar, S., Grierson, P., Mitchell, J., Lin, Y., de Castria, T., Zhen, D., Vu, P., Morelli, M., Kundranda, M. N., Dorigo, O., Maloney, D. G., Ward, et al  
LIPPINCOTT WILLIAMS & WILKINS.2025: TPS788
- **Presentation and Management of Highly Differentiated Follicular Carcinoma of Ovarian Origin With DICER1 Gene Variants.** *JCEM case reports*  
Seav, S., Atiq, M., Lo, Y. C., Shah, J., Dorigo, O., Dosiou, C.  
2024; 2 (12): luae223
- **Geographical patterns in obesity and other lifestyle risk factors associated with endometrial cancer diagnosis and survival: The Women's Health Initiative longitudinal cohort**  
Somasegar, S., Hedlin, H., Kurian, A., Kroenke, C., Dorigo, O., Stefanick, M.

ACADEMIC PRESS INC ELSEVIER SCIENCE.2024: S127

- **Safety and tolerability of CRX100, an NKT cell therapy combined with tumor-specific oncolytic vaccinia virus, among patients with recurrent, platinum-resistant ovarian cancer**  
Dorigo, O., Moser, J., Contag, P., Patel, S., Weng, W.  
ACADEMIC PRESS INC ELSEVIER SCIENCE.2024: S297
- **Recommended Guidelines for Screening for Underlying Malignancy in Extramammary Paget's Disease Based on Anatomic Subtype.** *Journal of the American Academy of Dermatology*  
Kibbi, N., Owen, J. L., Worley, B., Alam, M.  
2024
- **EVEREST-2: A seamless phase 1/2 study of A2B694, a mesothelin (MSLN) logic-gated Tmod CAR T-cell therapy, in patients with solid tumors that show MSLN expression and human leukocyte antigen (HLA)-A\*02 loss of heterozygosity (LOH).**  
Punekar, S., Hecht, J., Smith, C., Simeone, D. M., Dorigo, O., Boyd, L. R., Kirtane, K., Ward, J., Locke, F. L., Morelli, M., Block, M., Eskander, R., Langeberg, et al  
LIPPINCOTT WILLIAMS & WILKINS.2024
- **Trends in ovarian, fallopian tube, and primary peritoneal cancer incidence, mortality, and survival: A 15-year population-based analysis.** *Gynecologic oncology*  
Somasegar, S., Reddy, R. A., Chow, S., Dorigo, O., Renz, M., Karam, A.  
2024; 184: 190-197
- **Aberrant nuclear  $\beta$ -catenin distribution does not prognosticate recurrences of endometrioid endometrial cancers - A retrospective single-institutional study.** *Gynecologic oncology*  
Beshar, I., Moon, A. S., Darji, H., Liu, C., Jennings, M. T., Dorigo, O., Litkouhi, B., Diver, E. J., Karam, A. K., Howitt, B. E., Renz, M.  
2023; 179: 85-90
- **Does lymph node assessment change the prognostic significance of substantial LVSI and p53 status in endometrial endometrioid carcinoma?** *Gynecologic oncology*  
Hui, C., Mendoza, M. G., von Eyben, R., Dorigo, O., Litkouhi, B., Renz, M., Karam, A., Hammer, P. M., Howitt, B. E., Kidd, E.  
2023; 177: 150-156
- **Maveropepimut-S, an immune-educating therapy with durable clinical benefit in patients with recurrent ovarian cancer**  
Dorigo, O., Oza, A., Pejovic, T., Ghatage, P., Ghamande, S., Provencher, D., MacDonald, L., Ebrahimizadeh, W., Torrey, H., Kaliaperumal, V., Hirsch, H., Mody, K., Bramhecha, et al  
ACADEMIC PRESS INC ELSEVIER SCIENCE.2023: S70-S71
- **Adjuvant radiation therapy in early-stage endometrial cancer with abnormal beta-catenin expression is associated with improved local control.** *Gynecologic oncology*  
Hui, C., Mendoza, M. G., Snyder, J., Dorigo, O., Litkouhi, B., Renz, M., Karam, A., Devereaux, K., Howitt, B. E., Kidd, E. A.  
2023; 174: 42-48
- **Maveropepimut-S, a DPX-based immune-educating therapy, shows promising and durable clinical benefit in patients with recurrent ovarian cancer, a phase 2 trial.** *Clinical cancer research : an official journal of the American Association for Cancer Research*  
Dorigo, O., Oza, A. M., Pejovic, T., Ghatage, P., Ghamande, S., Provencher, D., MacDonald, L. D., Torrey, H., Kaliaperumal, V., Ebrahimizadeh, W., Hirsch, H. A., Bramhecha, Y., Vilella, et al  
2023
- **Monocytes - A Promising New TRAIL in Ovarian Cancer Cell Therapy.** *Clinical cancer research : an official journal of the American Association for Cancer Research*  
Chow, S., Dorigo, O.  
2022
- **ASO Visual Abstract: Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome, and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer (HGSOC). A Multicenter, Retrospective Study of the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium.** *Annals of surgical oncology*  
Glajzer, J., Castillo-Tong, D. C., Richter, R., Vergote, I., Kulbe, H., Vanderstichele, A., Ruscito, I., Trillsch, F., Mustea, A., Kreuzinger, C., Gourley, C., Gabra, H., Taube, et al  
2022

- **Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer: A Multicenter Retrospective Study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium.** *Annals of surgical oncology*  
Glajzer, J., Castillo-Tong, D. C., Richter, R., Vergote, I., Kulbe, H., Vanderstichele, A., Ruscito, I., Trillsch, F., Mustea, A., Kreuzinger, C., Gourley, C., Gabra, H., Taube, et al  
2022
- **Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup.** *The Lancet. Oncology*  
Vergote, I., Gonzalez-Martin, A., Lorusso, D., Gourley, C., Mirza, M. R., Kurtz, J., Okamoto, A., Moore, K., Kridelka, F., McNeish, I., Reuss, A., Votan, B., du Bois, et al  
2022; 23 (8): e374-e384
- **Technetium Tc 99m tilmanocept fails to detect sentinel lymph nodes in endometrial cancer.** *Gynecologic oncology reports*  
Reddy, R. A., Moon, A. S., Chow, S., Heilbronner, L., Howitt, B., Diver, E., Dorigo, O., Litkouhi, B., Renz, M., Karam, A.  
2022; 43: 101054
- **Revealing the human mucinome.** *Nature communications*  
Malaker, S. A., Riley, N. M., Shon, D. J., Pedram, K., Krishnan, V., Dorigo, O., Bertozzi, C. R.  
2022; 13 (1): 3542
- **Predictive biomarker for surgical outcome in patients with advanced primary high-grade serous ovarian cancer. Are we there yet? An analysis of the prospective biobank for ovarian cancer.** *Gynecologic oncology*  
Keunecke, C., Kulbe, H., Dreher, F., Taube, E. T., Chekerov, R., Horst, D., Hummel, M., Kessler, T., Pietzner, K., Kassuhn, W., Heitz, F., Muallem, M. Z., Lang, et al  
2022
- **A phase 1 open label, first in human trial to study safety and tolerability of NK-T cells combined with vvDD: An accelerated dose escalation in multiple tumor types.**  
Dorigo, O., Contag, P., Moser, J., Patel, S., Frohlich, M. W.  
AMER ASSOC CANCER RESEARCH.2022
- **Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial.** *Lancet (London, England)*  
Gershenson, D. M., Miller, A., Brady, W. E., Paul, J., Carty, K., Rodgers, W., Millan, D., Coleman, R. L., Moore, K. N., Banerjee, S., Connolly, K., Secord, A. A., O'Malley, et al  
2022; 399 (10324): 541-553
- **Cell-based immunotherapies in gynecologic cancers.** *Current opinion in obstetrics & gynecology*  
Lang, S. M., Dorigo, O.  
1800; 34 (1): 10-14
- **Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial** *LANCET*  
Gershenson, D. M., Miller, A., Brady, W. E., Paul, J., Carty, K., Rodgers, W., Millan, D., Coleman, R. L., Moore, K. N., Banerjee, S., Connolly, K., Secord, A., O'Malley, et al  
2022; 399 (10324): 541-553
- **Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial** *LANCET*  
Gershenson, D. M., Miller, A., Brady, W. E., Paul, J., Carty, K., Rodgers, W., Millan, D., Coleman, R. L., Moore, K. N., Banerjee, S., Connolly, K., Secord, A., O'Malley, et al  
2022; 399 (10324): 541-553
- **Evidence-Based Clinical Practice Guidelines for Extramammary Paget Disease.** *JAMA oncology*  
Kibbi, N., Owen, J. L., Worley, B., Wang, J. X., Harikumar, V., Downing, M. B., Aasi, S. Z., Aung, P. P., Barker, C. A., Bolotin, D., Bordeaux, J. S., Cartee, T. V., Chandra, et al  
2022
- **Abdominopelvic FLASH Irradiation Improves PD-1 Immune Checkpoint Inhibition in Preclinical Models of Ovarian Cancer.** *Molecular cancer therapeutics*  
Eggold, J. T., Chow, S., Melemenidis, S., Wang, J., Natarajan, S., Loo, P. E., Manjappa, R., Viswanathan, V., Kidd, E. A., Engleman, E., Dorigo, O., Loo, B. W., Rankin, et al

2021

- **IDENTIFICATION OF POTENTIAL RESPONSE PREDICTORS TO MAVEROPEPIMUT-S (DPX-SURVIVAC), A NOVEL T CELL ACTIVATING IMMUNOTHERAPY, IN PATIENTS WITH ADVANCED RECURRENT OVARIAN CANCER**  
Dorigo, O., Ebrahimzadeh, W., Kennedy, B., MacDonald, L., Fiset, S., Vilella, J., Amit, O., Pejovic, T., Ghatage, P., Ghamande, S., Provencher, D., Bramhecha, Y.  
BMJ PUBLISHING GROUP.2021: A380
- **Phase II Trial Evaluating Efficacy of a Fitbit Program for Improving the Health of Endometrial Cancer Survivors**  
Rahimy, E., Usoz, M., von Eyben, R., Fujimoto, D., Watanabe, D., Karam, A., Jairam-Thodla, A., Mills, M., Dorigo, O., Diver, E., Teng, N., English, D., Kidd, et al  
LIPPINCOTT WILLIAMS & WILKINS.2021: S13
- **Cancer-associated mesothelial cells promote ovarian cancer chemoresistance through paracrine osteopontin signaling.** *The Journal of clinical investigation*  
Qian, J., LeSavage, B. L., Hubka, K. M., Ma, C., Natarajan, S., Eggold, J. T., Xiao, Y., Fuh, K. C., Krishnan, V., Enejder, A., Heilshorn, S. C., Dorigo, O., Rankin, et al  
2021; 131 (16)
- **Classification of molecular subtypes of high-grade serous ovarian cancer by MALDI-Imaging.**  
Kassuhn, W., Klein, O., Darb-Esfahani, S., Lammert, H., Handzik, S., Taube, E. T., Schmitt, W. D., Dorigo, O., Horst, D., Keunecke, C., Dreher, F., George, J., Bowtell, et al  
LIPPINCOTT WILLIAMS & WILKINS.2021
- **Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2).** *Nature communications*  
Swisher, E. M., Kwan, T. T., Oza, A. M., Tinker, A. V., Ray-Coquard, I., Oaknin, A., Coleman, R. L., Aghajanian, C., Konecny, G. E., O'Malley, D. M., Leary, A., Provencher, D., Welch, et al  
2021; 12 (1): 2487
- **Long-term efficacy of megestrol acetate and tamoxifen in a recurrent adult granulosa cell tumor of the ovary.** *Gynecologic oncology reports*  
Moon, A. S., Dorigo, O.  
2021; 36: 100770
- **Classification of Molecular Subtypes of High-Grade Serous Ovarian Cancer by MALDI-Imaging.** *Cancers*  
Kassuhn, W., Klein, O., Darb-Esfahani, S., Lammert, H., Handzik, S., Taube, E. T., Schmitt, W. D., Keunecke, C., Horst, D., Dreher, F., George, J., Bowtell, D. D., Dorigo, et al  
2021; 13 (7)
- **Phase II trial evaluating efficacy of a Fitbit program for improving the health of endometrial cancer survivors.** *Gynecologic oncology*  
Rahimy, E. n., Usoz, M. n., von Eyben, R. n., Fujimoto, D. n., Watanabe, D. n., Karam, A. n., Jairam-Thodla, A. n., Mills, M. n., Dorigo, O. n., Diver, E. J., Teng, N. n., English, D. n., Kidd, et al  
2021
- **Prospective molecular classification of endometrial carcinomas: institutional implementation, practice, and clinical experience.** *Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc*  
Devereaux, K. A., Weiel, J. J., Pors, J., Steiner, D. F., Ho, C., Charu, V., Suarez, C. J., Renz, M., Diver, E., Karam, A., Litkouhi, B., Dorigo, O., Kidd, et al  
2021
- **Cell-based immunotherapy in gynecologic malignancies.** *Current opinion in obstetrics & gynecology*  
Kamat, K., Krishnan, V., Berek, J. S., Dorigo, O.  
2020
- **An enzymatic toolkit for selective proteolysis, detection, and visualization of mucin-domain glycoproteins**  
Shon, D., Malaker, S. A., Pedram, K., Yang, E., Krishnan, V., Dorigo, O., Bertozzi, C. R.  
OXFORD UNIV PRESS INC.2020: 1111–12
- **Development of Therapeutic Vaccines for Ovarian Cancer.** *Vaccines*  
Chow, S., Berek, J. S., Dorigo, O.  
2020; 8 (4)

- **FLASH irradiation enhances the therapeutic index of abdominal radiotherapy in mice**  
Natarajan, S., Levy, K., Wang, J., Chow, S., Eggold, J., Loo, P., Manjappa, R., Lartey, F. M., Schuler, E., Skinner, L., Rafat, M., Ko, R., Kim, et al  
AMER ASSOC CANCER RESEARCH.2020
- **Total abdominal ultra-rapid FLASH irradiation enhances the efficacy of PD-1 inhibition in preclinical models of ovarian cancer**  
Chow, S., Eggold, J. T., Levy, K., Wang, J., Manjappa, R., Breitkreutz, D. Y., Yu, A. S., Bush, K., Dorigo, O., Loo, B. W., Rankin, E. B.  
AMER ASSOC CANCER RESEARCH.2020
- **Minimally Invasive Surgery for Gynecologic Cancers-A Cautionary Tale.** *JAMA oncology*  
Karam, A., Dorigo, O.  
2020
- **Incorporating Parp-inhibitors in Primary and Recurrent Ovarian Cancer: A Meta-analysis of 12 phase II/III randomized controlled trials.** *Cancer treatment reviews*  
Ruscito, I., Bellati, F., Ray-Coquard, I., Mirza, M. R., du Bois, A., Gasparri, M. L., Costanzi, F., De Marco, M. P., Nuti, M., Caserta, D., Pignata, S., Dorigo, O., Sehouli, et al  
2020; 87: 102040
- **Infiltration of tumor by T cells following treatment with DPX-Survivac and intermittent low dose cyclophosphamide (CPA) leads to clinical responses in advanced recurrent ovarian cancer (OvCa).**  
Dorigo, O., MacDonald, L., Schindler, J., Bramhecha, Y., Torrey, H., Kaliaperumal, V., Hrytsenko, O., Dirk, B., Patterson, K., Stanford, M., Fiset, S.  
AMER SOC CLINICAL ONCOLOGY.2020
- **DPX-Survivac, a novel T-cell immunotherapy, to induce robust T-cell responses in advanced ovarian cancer**  
Dorigo, O., Fiset, S., MacDonald, L., Bramhecha, Y., Hrytsenko, O., Dirk, B., Rosu, G., Stanford, M.  
AMER SOC CLINICAL ONCOLOGY.2020
- **Sentinel Lymph Node Biopsies in Endometrial Cancer: Practice Patterns among Gynecologic Oncologists in the United States** *JOURNAL OF MINIMALLY INVASIVE GYNECOLOGY*  
Renz, M., Diver, E., English, D., Kidd, E., Dorigo, O., Karam, A.  
2020; 27 (2): 482–88
- **Vulvar sarcoma outcomes by histologic subtype: a Surveillance, Epidemiology, and End Results (SEER) database review.** *International journal of gynecological cancer : official journal of the International Gynecological Cancer Society*  
Johnson, S. n., Renz, M. n., Wheeler, L. n., Diver, E. n., Dorigo, O. n., Litkouhi, B. n., Behbakht, K. n., Howitt, B. n., Karam, A. n.  
2020
- **An enzymatic toolkit for selective proteolysis, detection, and visualization of mucin-domain glycoproteins.** *Proceedings of the National Academy of Sciences of the United States of America*  
Shon, D. J., Malaker, S. A., Pedram, K. n., Yang, E. n., Krishnan, V. n., Dorigo, O. n., Bertozzi, C. R.  
2020
- **Abdominal FLASH irradiation reduces radiation-induced gastrointestinal toxicity for the treatment of ovarian cancer in mice.** *Scientific reports*  
Levy, K. n., Natarajan, S. n., Wang, J. n., Chow, S. n., Eggold, J. T., Loo, P. E., Manjappa, R. n., Melemenidis, S. n., Lartey, F. M., Schüler, E. n., Skinner, L. n., Rafat, M. n., Ko, et al  
2020; 10 (1): 21600
- **OMENTAL MACROPHAGES REGULATE OVARIAN CANCER METASTATIC COLONIZATION THROUGH THE CCL6-CCR1 SIGNALING AXIS**  
Krishnan, V., Tallapragada, S., Schaar, B., Chanana, A., Rinker-Schaeffer, C., Dorigo, O.  
AMER ASSOC CANCER RESEARCH.2019: 162
- **Gestational Trophoblastic Neoplasia, Version 2.2019** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*  
Abu-Rustum, N. R., Yashar, C. M., Bean, S., Bradley, K., Campos, S. M., Chon, H., Chu, C., Cohn, D., Crispens, M., Damast, S., Dorigo, O., Eifel, P. J., Fisher, et al  
2019; 17 (11): 1374–91
- **THE HYPOXIC TUMOR-MESOTHELIAL NICHE PROMOTES OVARIAN CANCER METASTASIS THROUGH COLLAGEN REMODELING**  
Natarajan, S., Foreman, K., Soriano, M., Shehade, H., Fregoso, D., Eggold, J., Rosen, N. S., Heilshorn, S., Krieg, A. J., Krishnan, V., Dorigo, O., Sinha, S., Fuh, et al  
AMER ASSOC CANCER RESEARCH.2019: 168

- **ASCO 2019 meeting review.** *Journal of gynecologic oncology*  
Diver, E., Dorigo, O., Berek, J.  
2019; 30 (5): e107
- **Quantitative super-resolution microscopy of the mammalian glycocalyx**  
Mockl, L., Pedram, K., Roy, A., Krishnan, V., Gustavsson, A., Dorigo, O., Bertozzi, C., Moerner, W.  
AMER CHEMICAL SOC.2019
- **CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy.** *Nature*  
Barkal, A. A., Brewer, R. E., Markovic, M., Kowarsky, M., Barkal, S. A., Zaro, B. W., Krishnan, V., Hatakeyama, J., Dorigo, O., Barkal, L. J., Weissman, I. L.  
2019
- **C-C chemokine receptor type 1 is a prognostic indicator in ovarian cancer**  
Chanana, A. M., Krishnan, V., Tallapragada, S., Dorigo, O.  
AMER ASSOC CANCER RESEARCH.2019
- **DPX-Survivac and intermittent low-dose cyclophosphamide (CPA) with or without epacadostat (E) in the treatment of subjects with advanced recurrent epithelial ovarian cancer (DeCidE(1) trial): T cell responses and tumor infiltration correlate with tumor regression.**  
Tanyi, J., Dorigo, O., Oza, A. M., Strauss, J., Pejovic, T., Ghamande, S. A., Ghatage, P., Vilella, J. A., Fiset, S., MacDonald, L., Hrytsenko, O., Stanford, M., Newton, et al  
AMER SOC CLINICAL ONCOLOGY.2019
- **Collagen Remodeling in the Hypoxic Tumor-Mesothelial Niche Promotes Ovarian Cancer Metastasis** *CANCER RESEARCH*  
Natarajan, S., Foreman, K. M., Soriano, M., Rossen, N. S., Shehade, H., Fregoso, D. R., Eggold, J. T., Krishnan, V., Dorigo, O., Krieg, A. J., Heilshorn, S. C., Sinha, S., Fuh, et al  
2019; 79 (9): 2271–84
- **The mucin-selective protease StcE enables molecular and functional analysis of human cancer-associated mucins** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*  
Malaker, S. A., Pedram, K., Ferracane, M. J., Bensing, B. A., Krishnan, V., Pett, C., Yu, J., Woods, E. C., Kramer, J. R., Westerlind, U., Dorigo, O., Bertozzi, C. R.  
2019; 116 (15): 7278–87
- **Collagen remodeling in the hypoxic tumor-mesothelial niche promotes ovarian cancer metastasis.** *Cancer research*  
Natarajan, S., Foreman, K. M., Soriano, M. I., Rossen, N. S., Shehade, H., Fregoso, D. R., Eggold, J. T., Krishnan, V., Dorigo, O., Krieg, A. J., Heilshorn, S. C., Sinha, S., Fuh, et al  
2019
- **Quantitative Super-Resolution Microscopy of the Mammalian Glycocalyx.** *Developmental cell*  
Möckl, L. n., Pedram, K. n., Roy, A. R., Krishnan, V. n., Gustavsson, A. K., Dorigo, O. n., Bertozzi, C. R., Moerner, W. E.  
2019
- **The mucin-selective protease StcE enables molecular and functional analysis of human cancer-associated mucins.** *Proceedings of the National Academy of Sciences of the United States of America*  
Malaker, S. A., Pedram, K. n., Ferracane, M. J., Bensing, B. A., Krishnan, V. n., Pett, C. n., Yu, J. n., Woods, E. C., Kramer, J. R., Westerlind, U. n., Dorigo, O. n., Bertozzi, C. R.  
2019
- **Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology.** *Journal of the National Comprehensive Cancer Network : JNCCN*  
Koh, W., Abu-Rustum, N. R., Bean, S., Bradley, K., Campos, S. M., Cho, K. R., Chon, H. S., Chu, C., Clark, R., Cohn, D., Crispens, M. A., Damast, S., Dorigo, et al  
2019; 17 (1): 64–84
- **Sentinel lymph node biopsies in endometrial cancer - practice patterns among Gynecologic Oncologists in the United States.** *Journal of minimally invasive gynecology*  
Renz, M. n., Diver, E. n., English, D. n., Kidd, E. n., Dorigo, O. n., Karam, A. n.  
2019
- **Immunotherapy in Gynecologic Cancers: What We Know Now and Where We Are Headed.** *American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting*

- Levinson, K., Dorigo, O., Rubin, K., Moore, K.  
2019: e126–e140
- **A scalable filtration method for high throughput screening based on cell deformability.** *Lab on a chip*  
Gill, N. K., Ly, C., Nyberg, K. D., Lee, L., Qi, D., Tofig, B., Reis-Sobreiro, M., Dorigo, O., Rao, J., Wiedemeyer, R., Karlan, B., Lawrenson, K., Freeman, et al  
2018
  - **Cell-based immunotherapy in gynecologic malignancies.** *Current opinion in obstetrics & gynecology*  
Schaar, B., Krishnan, V., Tallapragada, S., Chanana, A., Dorigo, O.  
2018
  - **Hypoxic signaling in the tumor-mesothelial niche promotes collagen remodeling and ovarian cancer metastasis.**  
Foreman, K., Fuh, K., SorianoJAL, M., Dorigo, O., Krishnan, V., Shehade, H., Natarajan, S., Sinha, S., Krieg, A., Rankin, E.  
AMER ASSOC CANCER RESEARCH.2018: 57
  - **Omentum immune microenvironment: Metastatic niche for ovarian cancer**  
Krishnan, V., Raju, P. A., Vierkoetter, K., Patel, S., Youngyupipatkul, J., Tallapragada, S., Schaar, B., Folkins, A. K., Herzenberg, L. A., Dorigo, O.  
AMER ASSOC CANCER RESEARCH.2018
  - **Uterine Neoplasms, Version 1.2018 Clinical Practice Guidelines in Oncology** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*  
Koh, W., Abu-Rustum, N. R., Bean, S., Bradley, K., Campos, S. M., Cho, K. R., Chon, H., Chu, C., Cohn, D., Crispens, M., Damast, S., Dorigo, O., Eifel, et al  
2018; 16 (2): 170–99
  - **Cell-based immunotherapy in gynecologic malignancies.** *Current opinion in obstetrics & gynecology*  
Schaar, B. n., Krishnan, V. n., Tallapragada, S. n., Dorigo, O. n.  
2018; 30 (1): 23–30
  - **Tumor associated macrophages in gynecologic cancers.** *Gynecologic oncology*  
Krishnan, V. n., Schaar, B. n., Tallapragada, S. n., Dorigo, O. n.  
2018
  - **Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials** *ONCOTARGET*  
MacKay, H. J., Levine, D. A., Bae-Jump, V. L., Bell, D. W., McAlpine, J. N., Santin, A., Fleming, G. F., Mutch, D. G., Nephew, K. P., Wentzensen, N., Goodfellow, P. J., Dorigo, O., Nijman, et al  
2017; 8 (48): 84579–94
  - **Imaging of Tumor-Associated Macrophages in a Transgenic Mouse Model of Orthotopic Ovarian Cancer.** *Molecular imaging and biology*  
He, H., Chiu, A. C., Kanada, M., Schaar, B. T., Krishnan, V., Contag, C. H., Dorigo, O.  
2017
  - **Vulvar Cancer, Version 1.2017 Clinical Practice Guidelines in Oncology** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*  
Koh, W., Greer, B. E., Abu-Rustum, N. R., Campos, S. M., Cho, K. R., Chon, H. S., Chu, C., Cohn, D., Crispens, M. A., Dizon, D. S., Dorigo, O., Eifel, P. J., Fisher, et al  
2017; 15 (1): 92-120
  - **Improving Care With a Portfolio of Physician-Led Cancer Quality Measures at an Academic Center** *Improving Care With a Portfolio of Physician-Led Cancer Quality Measures at an Academic Center*  
Porter, J. B.  
2017; 13 (8): e673-e682
  - **Women's cancer: Advancing molecular and immunotherapy** *CURRENT PROBLEMS IN CANCER*  
Dorigo, O.  
2017; 41 (1): 7
  - **Immunotherapy in ovarian cancer** *CURRENT PROBLEMS IN CANCER*  
Krishnan, V., Berek, J. S., Dorigo, O.

2017; 41 (1): 48-63

- **Immunotherapy in ovarian cancer.** *Current problems in cancer*  
Krishnan, V., Berek, J. S., Dorigo, O.  
2016
- **Ovarian Cancer, Version 1.2016** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*  
Morgan, R. J., Armstrong, D. K., Alvarez, R. D., Bakkum-Gamez, J. N., Behbakht, K., Chen, L., Copeland, L., Crispens, M. A., DeRosa, M., Dorigo, O., Gershenson, D. M., Gray, H. J., Hakam, et al  
2016; 14 (9): 1134-1163
- **Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology.** *Journal of the National Comprehensive Cancer Network*  
Morgan, R. J., Armstrong, D. K., Alvarez, R. D., Bakkum-Gamez, J. N., Behbakht, K., Chen, L., Copeland, L., Crispens, M. A., DeRosa, M., Dorigo, O., Gershenson, D. M., Gray, H. J., Hakam, et al  
2016; 14 (9): 1134-1163
- **Hemophagocytic lymphohistiocytosis as a paraneoplastic syndrome associated with ovarian dysgerminoma.** *Gynecologic oncology reports*  
Nosratan-Baskovic, M., Tan, B., Folkins, A., Chisholm, K. M., Dorigo, O.  
2016; 17: 38-41
- **Pilot prospective evaluation of F-18-FPPRGD(2) PET/CT in patients with cervical and ovarian cancer** *EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING*  
Minamimoto, R., Karam, A., Jamali, M., Barkhodari, A., Gambhir, S. S., Dorigo, O., Iagaru, A.  
2016; 43 (6): 1047-1055
- **Screening cell mechanotype by parallel microfiltration** *SCIENTIFIC REPORTS*  
Qi, D., Gill, N. K., Santiskulvong, C., Sifuentes, J., Dorigo, O., Rao, J., Taylor-Harding, B., Wiedemeyer, W. R., Rowat, A. C.  
2015; 5
- **Macrophage Blockade Using CSF1R Inhibitors Reverses the Vascular Leakage Underlying Malignant Ascites in Late-Stage Epithelial Ovarian Cancer** *CANCER RESEARCH*  
Moughon, D. L., He, H., Schokrpur, S., Jiang, Z. K., Yaqoob, M., David, J., Lin, C., Iruela-Arispe, M. L., Dorigo, O., Wu, L.  
2015; 75 (22): 4742-4752
- **Uterine Sarcoma, Version 1.2016 Featured Updates to the NCCN Guidelines** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*  
Koh, W., Greer, B. E., Abu-Rustum, N. R., Apte, S. M., Campos, S. M., Cho, K. R., Chu, C., Cohn, D., Crispens, M. A., Dizon, D. S., Dorigo, O., Eifel, P. J., Fisher, et al  
2015; 13 (11): 1321-1331
- **Disseminated Intravascular Coagulation Complicating the Conservative Management of Placenta Percreta** *OBSTETRICS AND GYNECOLOGY*  
Judy, A. E., Lyell, D. J., Druzin, M. L., Dorigo, O.  
2015; 126 (5): 1016-1018
- **Single cell analysis of ascites macrophages in ovarian cancer**  
He, H., Yu, F., Quake, S. R., Dorigo, O.  
AMER ASSOC CANCER RESEARCH.2015
- **Parallel microfiltration (PMF): A novel method to screen cell mechanotype**  
Wiedemeyer, W., Qi, D., Gi, N., Santiskulvong, C., Dorigo, O., Rao, J., Taylor-Harding, B., Rowat, A. C.  
AMER ASSOC CANCER RESEARCH.2015
- **Comprehensive genomic profiling (CGP) of cervical squamous cell carcinoma (cSCC) to identify targeted therapy options.**  
Elvin, J., Bailey, M., Carneiro, B. A., Ali, S., Vergilio, J., Palma, N., Chmielecki, J., Frampton, G., Lipson, D., Stephens, P., Miller, V. A., Johnson, M., Giles, et al  
AMER SOC CLINICAL ONCOLOGY.2015
- **Cervical cancer, version 2.2015.** *Journal of the National Comprehensive Cancer Network*  
Koh, W., Greer, B. E., Abu-Rustum, N. R., Apte, S. M., Campos, S. M., Cho, K. R., Chu, C., Cohn, D., Crispens, M. A., Dorigo, O., Eifel, P. J., Fisher, C. M., Frederick, et al

2015; 13 (4): 395-404

- **Cervical Cancer, Version 2.2015 Featured Updates to the NCCN Guidelines** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*  
Koh, W., Greer, B. E., Abu-Rustum, N. R., Apte, S. M., Campos, S. M., Cho, K. R., Chu, C., Cohn, D., Crispens, M. A., Dorigo, O., Eifel, P. J., Fisher, C. M., Frederick, et al  
2015; 13 (4): 395-404
- **Immunotherapeutic approaches to ovarian cancer treatment.** *Journal for immunotherapy of cancer*  
Chester, C., Dorigo, O., Berek, J. S., Kohrt, H.  
2015; 3: 7-?
- **M2 macrophage inhibition reverses vascular leaks that cause malignant ascites in late-stage epithelial ovarian cancer**  
Moughon, D., He, H., Schokrpur, S., Jiang, Z., Yaqoob, M., David, J., Iruela-Arispe, L., Dorigo, O., Wu, L.  
AMER ASSOC CANCER RESEARCH.2015
- **Screening cell mechanotype by parallel microfiltration.** *Scientific reports*  
Qi, D., Kaur Gill, N., Santiskulvong, C., Sifuentes, J., Dorigo, O., Rao, J., Taylor-Harding, B., Ruprecht Wiedemeyer, W., Rowat, A. C.  
2015; 5: 17595-?
- **The role of tumor associated macrophages in ovarian cancer**  
He, H., Moughon, D. L., Hillerup, C., ElMasri, W., Wu, L., Dorigo, O.  
ACADEMIC PRESS INC ELSEVIER SCIENCE.2014: 385
- **Mutational analysis of serous ovarian cancer using Ion Torrent sequencing**  
Masghati, S., Dorigo, O., Santiskulvong, C.  
AMER ASSOC CANCER RESEARCH.2014
- **Increased risk and pattern of secondary malignancies in patients with invasive extramammary Paget disease.** *British journal of dermatology*  
Karam, A., Dorigo, O.  
2014; 170 (3): 661-671
- **Anti-N-methyl-aspartate receptor encephalitis in identical twin sisters: role for oophorectomy.** *Obstetrics and gynecology*  
Masghati, S., Nosratian, M., Dorigo, O.  
2014; 123 (2): 433-435
- **The role of Rho GTPase in cell stiffness and cisplatin resistance in ovarian cancer cells** *INTEGRATIVE BIOLOGY*  
Sharma, S., Santiskulvong, C., Rao, J., Gimzewski, J. K., Dorigo, O.  
2014; 6 (6): 611-617
- **MMPs in Ovarian Cancer as Therapeutic Targets** *ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY*  
Karam, A., Dorigo, O.  
2012; 12 (7): 764-772
- **Solid pseudopapillary neoplasm, pancreas type, presenting as a primary ovarian neoplasm** *HUMAN PATHOLOGY*  
Stoll, L. M., Parvataneni, R., Johnson, M. W., Gui, D., Dorigo, O., Sullivan, P.  
2012; 43 (8): 1339-1343
- **Expression of thyroid transcription factor-1 in normal endometrium is associated with risk of endometrial cancer development** *MODERN PATHOLOGY*  
Sullivan, P. S., Maresh, E. L., Seligson, D. B., Habeeb, O., Wadehra, M., Goodglick, L., Dorigo, O.  
2012; 25 (8): 1140-1148
- **Correlative nanomechanical profiling with super-resolution F-actin imaging reveals novel insights into mechanisms of cisplatin resistance in ovarian cancer cells** *NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE*  
Sharma, S., Santiskulvong, C., Bentolilla, L. A., Rao, J., Dorigo, O., Gimzewski, J. K.  
2012; 8 (5): 757-766
- **Treatment outcomes in a large cohort of patients with invasive Extramammary Paget's disease** *GYNECOLOGIC ONCOLOGY*  
Karam, A., Dorigo, O.  
2012; 125 (2): 346-351

- **Predictors of resolution of complex atypical hyperplasia or grade 1 endometrial adenocarcinoma in premenopausal women treated with progestin therapy** *GYNECOLOGIC ONCOLOGY*  
Penner, K. R., Dorigo, O., Aoyama, C., Ostrzega, N., Balzer, B. L., Rao, J., Walsh, C. S., Cass, I., Holschneider, C. H.  
2012; 124 (3): 542-548
- **Effect of PI3K/Akt Pathway Inhibition-Mediated G(1) Arrest on Chemosensitization in Ovarian Cancer Cells** *ANTICANCER RESEARCH*  
Fekete, M., Santiskulvong, C., Eng, C., Dorigo, O.  
2012; 32 (2): 445-452
- **Personalizing CA125 Levels for Ovarian Cancer Screening** *CANCER PREVENTION RESEARCH*  
Dorigo, O., Berek, J. S.  
2011; 4 (9): 1356-1359
- **Dual Targeting of Phosphoinositide 3-Kinase and Mammalian Target of Rapamycin Using NVP-BEZ235 as a Novel Therapeutic Approach in Human Ovarian Carcinoma** *CLINICAL CANCER RESEARCH*  
Santiskulvong, C., Konecny, G. E., Fekete, M., Chen, K. M., Karam, A., Mulholland, D., Eng, C., Wu, H., Song, M., Dorigo, O.  
2011; 17 (8): 2373-2384
- **Cisplatin and PI3kinase Inhibition Decrease Invasion and Migration of Human Ovarian Carcinoma Cells and Regulate Matrix-Metalloproteinase Expression** *CYTOSKELETON*  
Karam, A. K., Santiskulvong, C., Fekete, M., Zabih, S., Eng, C., Dorigo, O.  
2010; 67 (8): 535-544
- **Robust In Vivo Transduction of a Genetically Stable Epstein-Barr Virus Episome to Hepatocytes in Mice by a Hybrid Viral Vector** *JOURNAL OF VIROLOGY*  
Gallagher, S. D., Gil, J. S., Dorigo, O., Berk, A. J.  
2009; 83 (7): 3249-3257
- **Dual targeting of mammalian target of rapamycin and phosphoinositide 3-kinase using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma**  
Dorigo, O., Santiskulvong, C., Fekete, M., Karam, A., Mulholland, D., Eng, C., Wu, H.  
ACADEMIC PRESS INC ELSEVIER SCIENCE.2009: S9-S10
- **Death from Metastatic Donor-Derived Ovarian Cancer in a Male Kidney Transplant Recipient** *AMERICAN JOURNAL OF TRANSPLANTATION*  
Lipshutz, G. S., Mihara, N., Wong, R., Wallace, W. D., Allen-Auerbach, M., Dorigo, O., Rao, P. N., Pham, P. T., Pham, P. T.  
2009; 9 (2): 428-432
- **HER-2/neu targeting for recurrent vulvar Paget's disease A case report and literature review** *GYNECOLOGIC ONCOLOGY*  
Karam, A., Berek, J. S., Stenson, A., Rao, J., Dorigo, O.  
2008; 111 (3): 568-571
- **CA125: Megadaltos of novel opportunities** *GYNECOLOGIC ONCOLOGY*  
Dorigo, O., Berek, J. S.  
2007; 104 (3): 505-507
- **Enhanced expression of hypersensitive alpha 4\*nAChR in adult mice increases the loss of midbrain dopaminergic neurons** *FASEB JOURNAL*  
Schwarz, J., Schwarz, S. C., Dorigo, O., Stuetzer, A., Wegner, F., Labarca, C., Deshpande, P., Gil, J. S., Berk, A. J., Lester, H. A.  
2006; 20 (7): 935-946
- **Enhanced Expression of L9'S Mutant nAChR in Adult Mice Increases the Loss of Midbrain Dopaminergic Neurons** *The Journal of the Federation of American Societies for Experimental Biology*  
Schwarz, J., Schwarz, S. C., Dorigo, O., Labarca, C., Deshpande, P., Gil, J., Berk, A., Lester, H. A.  
2006: 935-946
- **Development of a novel helper-dependent adenovirus-Epstein-Barr virus hybrid system for the stable transformation of mammalian cells** *JOURNAL OF VIROLOGY*  
Dorigo, O., Gil, J. S., Gallagher, S. D., Tan, B. T., Castro, M. G., Lowenstein, P. R., Calos, M. P., Berk, A. J.  
2004; 78 (12): 6556-6566

- **Enhanced expression of L9'S mutant alpha 4 nAChR in adult mice increases the loss of midbrain dopaminergic neurons** *8th International Congress of Parkinsons Disease and Movement Disorders*  
Schwarz, S. C., Dorigo, O., Labarca, C., Berk, A. J., Lester, H. A., Schwarz, J.  
WILEY-LISS.2004: S42-S42
- **Specific keynote: Immunological therapy for ovarian cancer** *8th International Forum on Ovarian Cancer*  
Berek, J. S., Dorigo, O., Schultes, B., Nicodemus, C.  
ACADEMIC PRESS INC ELSEVIER SCIENCE.2003: S105-S109
- **Antigenic and immunologic characterization of an allogeneic colon carcinoma vaccine** *CLINICAL AND EXPERIMENTAL IMMUNOLOGY*  
Shawler, D. L., Bartholomew, R. M., Garrett, M. A., Trauger, R. J., Dorigo, O., Van Beveren, C., MARCHESE, A., Ferre, F., Duffy, C., Carlo, D. J., Sherman, L. A., Gold, D. P., SOBOL, et al  
2002; 129 (1): 99-106
- **A radical debulking of leiomyomatosis peritonealis disseminata from a colonic obstruction: A case report and review of the literature** *JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS*  
Ghosh, K., Dorigo, O., Bristow, R., Berek, J.  
2000; 191 (2): 212-215
- **IL-2 plasmid therapy of murine ovarian carcinoma inhibits the growth of tumor ascites and alters its cytokine profile** *JOURNAL OF IMMUNOLOGY*  
Horton, H. M., Dorigo, O., Hernandez, P., Anderson, D., Berek, J. S., Parker, S. E.  
1999; 163 (12): 6378-6385
- **Combination of transforming growth factor beta antisense and interleukin-2 gene therapy in the murine ovarian teratoma model** *GYNECOLOGIC ONCOLOGY*  
Dorigo, O., Shawler, D. L., Royston, I., SOBOL, R. E., Berek, J. S., Fakhrai, H.  
1998; 71 (2): 204-210
- **Sensitization of rat glioblastoma multiforme to cisplatin in vivo following restoration of wild-type p53 function** *JOURNAL OF NEUROSURGERY*  
Dorigo, O., Turla, S. T., Lebedeva, S., Gjerset, R. A.  
1998; 88 (3): 535-540
- **Gene therapy for ovarian cancer – Molecular scissors of the new millenium?** *Journal of Gynecologic Techniques*  
Dorigo, O., Berek, J. S.  
1998; 4: 149-162
- **Synergy of transforming growth factor beta (TGF-beta) antisense and IL-2 gene therapy in the murine ovarian teratoma model** *Gynecologic Oncology*  
Dorigo, O., Shawler, D. L., Royston, I., Sobol, R. E., Berek, J. S., Fakhrai, H.  
1998: 204-210
- **Progress and prospects in vaccine therapy for gynecologic cancers.** *Oncology (Williston Park, N.Y.)*  
Gurski, K. J., Steller, M. A.  
1997; 11 (11): 1727-?
- **Construction and characterization of retroviral vectors for interleukin-2 gene therapy** *JOURNAL OF IMMUNOTHERAPY*  
Fakhrai, H., Shawler, D. L., VANBEVEREN, C., Lin, H., Dorigo, O., Solomon, M. J., Gjerset, R. A., Smith, L., Bartholomew, R. M., Boggiano, C. A., Gold, D. P., SOBOL, R. E.  
1997; 20 (6): 437-448
- **Gene therapy for ovarian cancer: Development of novel treatment strategies** *INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER*  
Dorigo, O., Berek, J. S.  
1997; 7 (1): 1-13
- **Interleukin-2 (IL-2) gene therapy with allogeneic fibroblasts in the CT-26 model of murine colorectal carcinoma** *ONCOLOGY REPORTS*  
Shawler, D. L., Dorigo, O., VANBEVEREN, C., Bartholomew, R. M., Fakhrai, H., SOBOL, R. E.  
1997; 4 (1): 135-138
- **Interleukin-2 (IL-2) gene therapy with allogenic fibroblasts in the CT-26 model of murine colorectal carcinoma** *Oncology Reports*

- Shawler, D. L., Dorigo, O., Van Beveren, C., Bartholomew, R. M., Fakhrai, H., Sobol, R. E.  
1997; 4 (N1): 135-138
- **Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*  
Fakhrai, H., Dorigo, O., Shawler, D. L., Lin, H., MERCOLA, D., Black, K. L., Royston, I., SOBOL, R. E.  
1996; 93 (7): 2909-2914
  - **Immuno-gene therapy of colon carcinoma and central nervous tumors** *In: Gene Therapy and Cancer*  
Sobol, R. E., Fakhrai, H., Shawler, D. L., Dorigo, O., Gjerset, R. A., Mercola, D., Koziol, J., Royston, I., Bartholomew, R.  
1996
  - **COMPARISON OF GENE-THERAPY WITH INTERLEUKIN-2 GENE MODIFIED FIBROBLASTS AND TUMOR-CELLS IN THE MURINE CT-26 MODEL OF COLORECTAL-CARCINOMA** *JOURNAL OF IMMUNOTHERAPY*  
Shawler, D. L., Dorigo, O., Gjerset, R. A., Royston, I., SOBOL, R. E., Fakhrai, H.  
1995; 17 (4): 201-208
  - **INTERLEUKIN-2 GENE-THERAPY IN A PATIENT WITH GLIOBLASTOMA** *GENE THERAPY*  
SOBOL, R. E., Fakhrai, H., Shawler, D., GJERSET, R., Dorigo, O., Carson, C., KHALEGHI, T., KOZIOL, J., Shifan, T. A., Royston, I.  
1995; 2 (2): 164-167
  - **CHARACTERIZATION OF A NEW HUMAN GLIOBLASTOMA CELL-LINE THAT EXPRESSES MUTANT P53 AND LACKS ACTIVATION OF THE PDGF PATHWAY IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL**  
Gjerset, R. A., Fakhrai, H., Shawler, D. L., Turla, S., Dorigo, O., GROVERBARDWICK, A., MERCOLA, D., Wen, S. F., Collins, H., Lin, H., Garcia, M. V., Kruse, C. A., Royston, et al  
1995; 31 (3): 207-214
  - **INJECTION OF COLON-CARCINOMA PATIENTS WITH AUTOLOGOUS IRRADIATED TUMOR-CELLS AND FIBROBLASTS GENETICALLY-MODIFIED TO SECRETE INTERLEUKIN-2 (IL-2) - A PHASE-I STUDY** *HUMAN GENE THERAPY*  
SOBOL, R. E., Royston, I., Fakhrai, H., Shawler, D. L., Carson, C., Dorigo, O., GJERSET, R., Gold, D. P., KOZIOL, J., MERCOLA, D., VANBEVEREN, C., Wilson, D.  
1995; 6 (2): 195-204
  - **Apoptosis of CD4+ and CD8+ cells from HIV-1 infected individuals: role of anti-idiotypic antibodies** *Vaccine Research*  
Muller, S., Brams, P., Collins, H., Dorigo, O., Kohler, H.  
1995; Vol 4 (No 4): 229-238
  - **VALUE OF BOWEL RESECTION AND PREOPERATIVE COLOSCOPY IN OVARIAN-CANCER** *49th Meeting of the Deutschen-Gesellschaft-fur-Gynakologie-und-Geburtshilfe*  
Dorigo, O., Meier, W., Scheidel, P., Hepp, H.  
SPRINGER HEIDELBERG.1993: 966-68
  - **LYMPHOCYTE SUBPOPULATIONS IN WOMEN WITH MALIGNANT-TUMORS IN CORRELATION WITH KNOWN PROGNOSTIC FACTORS AND AS DISEASE PARAMETERS DURING CYTOKINE THERAPY** *49th Meeting of the Deutschen-Gesellschaft-fur-Gynakologie-und-Geburtshilfe*  
ROMISCH, M., Bauer, F., Daponte, A., Meier, W., Dorigo, O., Eiermann, W.  
SPRINGER HEIDELBERG.1993: 1091-93
  - **ACTIVATION OF NEUTROPHILS IN THE MICROVASCULATURE OF THE ISCHEMIC AND REPERFUSED MYOCARDIUM** *2nd Symposium of the German-Heart-Institute - Coronary Endothelium and Smooth Muscle : Basic Aspects and Clinical Consequences*  
Tillmanns, H., Neumann, F. J., Tiefenbacher, C., Dorigo, O., Parekh, N., Waas, W., Zimmermann, R., Steinhausen, M., Kuebler, W.  
W B SAUNDERS CO LTD.1993: 82-86
  - **A NON-LYMPHOMA IDIOTYPE IS INDICATIVE AND PREDICTIVE FOR B-CELL MALIGNANCIES IN AIDS** *1ST INTERNATIONAL MEETING ON IMMUNOLOGICAL APPROACHES TO TUMOR THERAPY BY ANTIBODIES AND TUMOR CELL VACCINES*  
Herndier, B., McGrath, M., Abbey, N., Wang, H. T., Ng, V., Dorigo, O., Kaplan, L., Muller, S., Kohler, H.  
MARY ANN LIEBERT INC.1993: 529-37
  - **A MONOCLONAL-ANTIBODY (IF7) SPECIFIC FOR HUMAN ANTI-HIV IG INDUCES APOPTOSIS AND INHIBITS CTL ACTIVITY IN CD8+ LYMPHOCYTES FROM HIV-1 INFECTED INDIVIDUALS**  
Muller, S., Collins, H., Brams, P., Wang, H., Dorigo, O., McGrath, M., Grant, M., Rosenthal, K., Kohler, H.  
WILEY-BLACKWELL.1993: 68-68

- **NEW TECHNIQUES FOR THE STUDY OF THE CORONARY MICROCIRCULATION - IMPORTANCE OF MEASUREMENTS OF CORONARY FLOW RESERVE IN THE CLINICAL SETTING** *CORONARY ARTERY DISEASE*  
Tillmanns, H., Neumann, F. J., Waas, W., Mall, G., Parekh, N., Tiefenbacher, C., Dorigo, O., Zimmermann, R., Dart, A. M., Steinhausen, M., Kubler, W.  
1992; 3 (7): 586-592
- **SHORT-TERM OUTCOME IN INFANTS WITH BIRTH WEIGHTS LESS-THAN 1750-G BORN TO MOTHERS WITH HELLP SYNDROME** *JOURNAL OF PERINATAL MEDICINE*  
Gortner, L., Pohlandt, F., Bartmann, P., Terinde, R., Versmold, H., Dorigo, O.  
1992; 20 (1): 25-28
- **PHARMACOLOGICAL EFFECTS ON CORONARY MICROVESSELS DURING MYOCARDIAL-ISCHEMIA** *EUROPEAN HEART JOURNAL*  
Tillmanns, H., Neumann, F. J., Parekh, N., Dorigo, O., Tiefenbacher, C., Zimmermann, R., Steinhausen, M., Kubler, W.  
1990; 11: 10-15
- **MICROCIRCULATION IN THE HYPERTROPHIC AND ISCHEMIC HEART** *EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY*  
Tillmanns, H., Neumann, F. J., Parekh, N., Zimmermann, R., Tiefenbacher, C., Dorigo, O., Steinhausen, M., Kubler, W.  
1990; 39: S9-S12